Christof Seidl is a research associate at the Department of Nuclear Medicine at the Technische Universität München (TUM). He studied Biology in Berlin and Munich and received his PhD from the Ludwig-Maximilians Universität München (LMU) in 1994. Currently, his focus lies on the application of conjugates composed of the alpha-emitters Bi-213 and Ac-225 coupled to carriers (peptides or antibodies) that specifically target tumor cells. He has analyzed therapeutic efficacy of such alpha-emitter conjugates in various tumor models including gastric, ovarian and bladder cancer. A first pilot study using intravesical instillation of Bi-213-anti-EGFR-MAb in BCG-refractory patients suffering from carcinoma in situ (CIS) of the bladder has been carried out at TUM. Christof has been a member of the Scientific Committee of ‘The 11th International Symposium on Targeted-Alpha-Therapy (TAT11)’ held in Ottawa (Canada) in April 2019. Moreover, he has written a detailed review article entitled ‘Radioimmunotherapy with α-particle-emitting radionuclides’ that appeared in ‘Immunotherapy’ in 2014.